The Efficacy of A New Crosslinked Hyaluronan Gel in Prevention of Intrauterine Adhesion
Primary Purpose
Intrauterine Adhesion
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
new crosslinked hyaluronan gel
Sponsored by
About this trial
This is an interventional prevention trial for Intrauterine Adhesion focused on measuring Intrauterine adhesion, Delayed miscarriage, hyaluronan gel
Eligibility Criteria
The inclusion criteria:
- Patients to be female, aged 18-45 years
- Without previous dilatation and curettage
- Undergoing dilatation and curettage for the current delayed miscarriage
- All participants should be with normal liver/rental function and without systemic disease
- Agree to use adequate forms of contraception throughout the study
- Be in good compliance with the follow-up examination according to the study protocol.
The exclusion criteria:
- Known/suspected intolerance or hypersensitivity to hyaluronan or its derivatives
- Genital tract malformation
- Inflammation of genital tract or pelvic cavity, clinical evidence of cancer in genital tract
- Suspected genital tuberculosis
- Abnormal blood coagulation
- Medical histories of peripheral vascular disease, alcohol/drug abuse, and mental illness
- Acute or severe infection
- Autoimmune diseases.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Treatment
Control
Arm Description
At the end of the dilatation and curettage, new crosslinked hyaluronan gel (3ml) was applied to the uterine cavity in women assigned to the treatment group through a 15-cm sterile cannula.
At the end of the dilatation and curettage, nothing was applied to the uterine cavity in women assigned to the control group.
Outcomes
Primary Outcome Measures
Incidence of intrauterine adhesion
The number of women with intrauterine adhesion
Secondary Outcome Measures
The adhesion scores of extent of uterine cavity involved
Evaluated according to American Fertility Society classification of intrauterine adhesion during the follow-up diagnostic hysteroscopy: 1 point (<1/3 cavity with adhesion), 2 points (1/3-2/3 cavity with adhesion) and 4 points (>2/3 cavity with adhesion), high values represent worse outcome
The adhesion scores of type of adhesion
Evaluated according to American Fertility Society classification of intrauterine adhesion during the follow-up diagnostic hysteroscopy: 1 point (filmy adhesion), 2 points (filmy & dense adhesion) and 4 points (dense adhesion), high values represent worse outcome
The adhesion scores of menstrual pattern
Evaluated according to American Fertility Society classification of intrauterine adhesion during the follow-up diagnostic hysteroscopy: 0 point (normal), 2 points (hypomenorrhea) and 4 points (amenorrhea), high values represent worse outcome
Cumulative adhesion score
The summed score of the adhesion scores of extent of uterine cavity involved, type of adhesion and menstrual pattern; range: 1-12 points, high values represent worse outcome
Severity
Graded according to cumulative adhesion score: Stage I (mild)(1-4 points), Stage II (moderate)(5-8 points) and Stage III (severe)(9-12 points).
Full Information
NCT ID
NCT03353909
First Posted
October 10, 2017
Last Updated
November 23, 2017
Sponsor
BioRegen Biomedical (CHangzhou) Co., Ltd
1. Study Identification
Unique Protocol Identification Number
NCT03353909
Brief Title
The Efficacy of A New Crosslinked Hyaluronan Gel in Prevention of Intrauterine Adhesion
Official Title
The Efficacy of A New Crosslinked Hyaluronan Gel in the Prevention of Postoperative Intrauterine Adhesion After Dilatation and Curettage in Women With Delayed Miscarriage: A Prospective, Randomized, Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
November 2017
Overall Recruitment Status
Completed
Study Start Date
July 1, 2016 (Actual)
Primary Completion Date
February 15, 2017 (Actual)
Study Completion Date
February 15, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
BioRegen Biomedical (CHangzhou) Co., Ltd
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Using American Fertility Society classification of intrauterine adhesions, the efficacy of a new crosslinked hyaluronan gel in reducing intrauterine adhesion formation after dilatation and curettage for delayed miscarriage in women without previous dilatation and curettage was examined.
Detailed Description
Study Objectives: To evaluate the efficacy of a new crosslinked hyaluronan gel in reducing intrauterine adhesions formation after dilatation and curettage.
Design: Randomized controlled trial. Settings: Six hospitals for maternal and child health care in China. Patients: Three hundred women undergoing dilatation and curettage for delayed miscarriage without previous dilatation and curettage.
Interventions: Women were randomly assigned into either dilatation and curettage alone group or dilatation and curettage plus new crosslinked hyaluronan gel application group with 1:1 allocation.
Measurements and Outcomes: All patients were evaluated using American Fertility Society classification of IUAs during the follow-up diagnostic hysteroscopy, scheduled 3 months after dilatation and curettage procedure. The primary outcome was the number of women with IUAs, and the secondary outcome was the adhesion scores and the severity of IUAs.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intrauterine Adhesion
Keywords
Intrauterine adhesion, Delayed miscarriage, hyaluronan gel
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
300 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Treatment
Arm Type
Experimental
Arm Description
At the end of the dilatation and curettage, new crosslinked hyaluronan gel (3ml) was applied to the uterine cavity in women assigned to the treatment group through a 15-cm sterile cannula.
Arm Title
Control
Arm Type
No Intervention
Arm Description
At the end of the dilatation and curettage, nothing was applied to the uterine cavity in women assigned to the control group.
Intervention Type
Device
Intervention Name(s)
new crosslinked hyaluronan gel
Other Intervention Name(s)
MateRegen Gel
Intervention Description
At the end of the dilatation and curettage, new crosslinked hyaluronan gel was applied to the uterine cavity.
Primary Outcome Measure Information:
Title
Incidence of intrauterine adhesion
Description
The number of women with intrauterine adhesion
Time Frame
3 months after dilatation and curettage
Secondary Outcome Measure Information:
Title
The adhesion scores of extent of uterine cavity involved
Description
Evaluated according to American Fertility Society classification of intrauterine adhesion during the follow-up diagnostic hysteroscopy: 1 point (<1/3 cavity with adhesion), 2 points (1/3-2/3 cavity with adhesion) and 4 points (>2/3 cavity with adhesion), high values represent worse outcome
Time Frame
3 months after dilatation and curettage
Title
The adhesion scores of type of adhesion
Description
Evaluated according to American Fertility Society classification of intrauterine adhesion during the follow-up diagnostic hysteroscopy: 1 point (filmy adhesion), 2 points (filmy & dense adhesion) and 4 points (dense adhesion), high values represent worse outcome
Time Frame
3 months after dilatation and curettage
Title
The adhesion scores of menstrual pattern
Description
Evaluated according to American Fertility Society classification of intrauterine adhesion during the follow-up diagnostic hysteroscopy: 0 point (normal), 2 points (hypomenorrhea) and 4 points (amenorrhea), high values represent worse outcome
Time Frame
3 months after dilatation and curettage
Title
Cumulative adhesion score
Description
The summed score of the adhesion scores of extent of uterine cavity involved, type of adhesion and menstrual pattern; range: 1-12 points, high values represent worse outcome
Time Frame
3 months after dilatation and curettage
Title
Severity
Description
Graded according to cumulative adhesion score: Stage I (mild)(1-4 points), Stage II (moderate)(5-8 points) and Stage III (severe)(9-12 points).
Time Frame
3 months after dilatation and curettage
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
The inclusion criteria:
Patients to be female, aged 18-45 years
Without previous dilatation and curettage
Undergoing dilatation and curettage for the current delayed miscarriage
All participants should be with normal liver/rental function and without systemic disease
Agree to use adequate forms of contraception throughout the study
Be in good compliance with the follow-up examination according to the study protocol.
The exclusion criteria:
Known/suspected intolerance or hypersensitivity to hyaluronan or its derivatives
Genital tract malformation
Inflammation of genital tract or pelvic cavity, clinical evidence of cancer in genital tract
Suspected genital tuberculosis
Abnormal blood coagulation
Medical histories of peripheral vascular disease, alcohol/drug abuse, and mental illness
Acute or severe infection
Autoimmune diseases.
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
29678756
Citation
Li X, Wu L, Zhou Y, Fan X, Huang J, Wu J, Yu R, Lou J, Yang M, Yao Z, Xue M. New Crosslinked Hyaluronan Gel for the Prevention of Intrauterine Adhesions after Dilation and Curettage in Patients with Delayed Miscarriage: A Prospective, Multicenter, Randomized, Controlled Trial. J Minim Invasive Gynecol. 2019 Jan;26(1):94-99. doi: 10.1016/j.jmig.2018.03.032. Epub 2018 Apr 17.
Results Reference
derived
Learn more about this trial
The Efficacy of A New Crosslinked Hyaluronan Gel in Prevention of Intrauterine Adhesion
We'll reach out to this number within 24 hrs